A typical patient with a rheumatic disease needs a multifaceted treatment approach to address comorbidities, minimize disability, promote quality of life and improve survival. To achieve these outcomes, rheumatology research has evolved from examining a single treatment to studying the best treatment approaches. Examples of these strategy trials include how to best combine pharmaceutical therapies,…
Data from multiple clinical trials and an extension study showed baricitinib is safe and effective for the long-term treatment of adults with RA…
The evaluation of a child with arthralgia who has a normal physical examination provides a challenge to rheumatologists. Here are some insights into assessing and treating children with musculoskeletal pain syndromes…
Big data can benefit rheumatology research. But according to experts at the 2018 ACR/ARHP Annual Meeting, the data must first be accessible, interoperable and shareable…
In a study, RA patients taking upadactinib monotherapy experienced less pain and morning joint stiffness than methotrexate-treated patients…
New research has linked the risk of developing interstitial lung disease in rheumatoid arthritis patients with the promoter variant in MUC5B, which may also contribute to the development of idiopathic pulmonary fibrosis and an unsual interstitial pneumonia seen by high-resolution CT scan…
Chairing the ACR’s Communications and Marketing Committee (CMC) can be a monumental task: The CMC is responsible for both internal and external communications to a variety of people, including rheumatology providers, patients, lawmakers, the pharmaceutical industry and others. But the CMC’s newest chair, Suleman Bhana, MD, FACR, is up for the job. The Rheumatologist recently…
Rheumatologists may benefit from the decentralized technology that makes cryptocurrency possible: blockchain. According to Anh L. Ngo, MD, MBA, using blockchain in healthcare may increase payment and purchasing efficiency and revolutionize EHR management…
The FDA has approved halobetasol propionate lotion as a topical treatment for plaque psoriasis…
The FDA has approved an update for rituximab’s label, which will include safety and efficacy information for treating ANCA-associated vasculitis…